Matthew Francis Dunn

Title: Innovations of Matthew Francis Dunn

Introduction

Matthew Francis Dunn is an accomplished inventor based in Middletown, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target kappa opioid receptors. His work is crucial for addressing various neurological and psychiatric disorders.

Latest Patents

Dunn holds a patent for "Heteroarylphenoxy benzamide kappa opioid ligands." This invention provides compounds of Formula I and pharmaceutically acceptable salts thereof. The patent outlines processes for the preparation of these compounds, intermediates used in their preparation, and compositions containing such compounds or salts. The applications of these compounds are aimed at treating kappa opioid-associated disorders, including neurological disorders, substance abuse disorders, and various psychiatric conditions.

Career Highlights

Matthew Francis Dunn is currently employed at Pfizer Corporation, a leading global pharmaceutical company. His role involves research and development of innovative therapeutic solutions. His expertise in pharmacology and medicinal chemistry has positioned him as a valuable asset in the industry.

Collaborations

Dunn collaborates with notable colleagues, including Natasha Mariam Kablaoui and Michael Eric Green. Their combined efforts contribute to advancing research in the field of opioid-related therapies.

Conclusion

Matthew Francis Dunn's innovative work in developing kappa opioid ligands represents a significant advancement in treating complex disorders. His contributions to Pfizer Corporation and the pharmaceutical industry highlight the importance of research and collaboration in driving medical innovations.